Equillium, Inc. · NASDAQ:EQ

Equillium — Investor Presentation (November 2024)

51 slides from Equillium's investor presentation, November 2024

  1. Slide 1: Corporate Presentation

    Corporate Presentation November 2024

  2. Slide 2: Forward-Looking Statements and Other Disclaimers

    Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “

  3. Slide 3: Equillium: Investment Highlights

    Equillium: Investment Highlights Anticipated Milestones Commercial Rights to Itolizumab Derisked • Phase 3 aGVHD topline data – Itolizumab • EQUATOR Phase 3 interim safety and potential to accelerate to Q1 2025 efficacy review July 2024: IDMC (modified study) • Full commercial rights to all recommen

  4. Slide 4: Diversified Pipeline of Differentiated Immunology Assets

    Diversified Pipeline of Differentiated Immunology Assets Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Rights Status FDA Fast Track & Enrollment paused: Potential acceleration acute graft-versus-host disease Orphan Drug Designations of topline data to Q1 2025 US, CAN, EQ001 FDA Fast Track AUS & NZ

  5. Slide 5: Itolizumab Safety Data & Clinical Results

    Itolizumab Safety Data & Clinical Results First-in-Class immune- modifying mAb targeting Mechanism of Action the CD6-ALCAM signaling pathway Acute Graft-Versus-Host Disease Ulcerative Colitis

  6. Slide 6: Itolizumab: Critical Mass of Safety Data and Positive Clinical Results

    Itolizumab: Critical Mass of Safety Data and Positive Clinical Results Over 1,000 subjects dosed with itolizumab across numerous clinical studies Acute GVHD - Pivotal Phase 3 (ongoing) IDMC Interim Review @ 100 patients in July 2024; recommended study should proceed Acute GVHD - Phase 1b (completed)

  7. Slide 7: CD6-ALCAM Pathway is Central to Immuno-Inflammation

    CD6-ALCAM Pathway is Central to Immuno-Inflammation CD6 is a co-stimulatory receptor overexpressed on Teff Teff cell and down-regulated on Treg activation CD6High cells exhibit greater pathogenic capacity Activated leukocyte cell adhesion molecule (ALCAM), is expressed on both antigen-presenting cel

  8. Slide 8: CD6 High Cells Exhibit Greater Pathogenic Capacity

    CD6High Cells Exhibit Greater Pathogenic Capacity Highest levels of CD6 are found on activated T effector cells (Teff) and associated with amplification of the auto-reactive cascade CD6low/- CD6high • Low proliferation • High Proliferation T reg • Regulatory phenotype T eff • Pathogenic Phenotypes •

  9. Slide 9: Itolizumab-induced Loss of Cell Surface CD6 Inhibits Teff Cells

    Itolizumab-induced Loss of Cell Surface CD6 Inhibits Teff Cells Itolizumab leads to loss of CD6 in both a dose and time-dependent manner resulting in T cells that are hyporesponsive to TCR stimulation† Pathogenic CD6hi ✱✱✱ Teff Cells 20000 ✱✱ 500000 (MFI normalized to Isotype) 1.2 Surface CD6 Expres

  10. Slide 10: A Differentiated Approach to Treating Immuno-Inflammatory Disease

    A Differentiated Approach to Treating Immuno-Inflammatory Disease Selectively targets auto-reactive effector T cells, while sparing regulatory T cells to promote immune tolerance and homeostasis, resulting in durable disease remission Synergistic inhibition of multiple Inhibition of Teff Restoration

  11. Slide 11: Itolizumab in GVHD: Executive Summary

    Itolizumab in GVHD: Executive Summary • Positive topline data from Phase 1b EQUATE study in acute graft-versus-host disease • Achieved CR and ORR at Day 29 of 48% and 65%, respectively* • Response at Day 29 was associated with improved progression-free survival through 1 year • Responders were able

  12. Slide 12: GVHD Competitive Landscape

    GVHD Competitive Landscape Growing strategic interest in GVHD with recently demonstrated market potential: JAKAFI: US sales in SR-aGVHD and 2L cGVHD estimated at $500M REZUROCK: US sales in 2L cGVHD estimated at $425M, ~3 years into launch (acquired by Sanofi $1.9B in 2021) Prophylaxis 1L acute GVHD

  13. Slide 13: Standard of Care: High-Dose Steroids Achieve Poor CR Outcomes

    Standard of Care: High-Dose Steroids Achieve Poor CR Outcomes MacMillan Steroids alone yield poor Complete Response rates et al. 2015 (steroids alone) GRAVITAS-301 (steroids alone) EQUATE (itolizumab + steroids) in high-risk aGVHD 100% Complete Responses are associated with improved Standard risk Hi

  14. Slide 14: EQUATOR Study: First-line Treatment of High-Risk aGVHD

    EQUATOR Study: First-line Treatment of High-Risk aGVHD Over 50 US clinical sites active, including 9 of top 10 U.S. allogeneic HSCT centers High exposure of itolizumab to key hospital systems and KOLs Phase 3 randomized, double-blind, global pivotal study of itolizumab in ~ 200 patients John Koreth,

  15. Slide 15: Itolizumab in Ulcerative Colitis: Executive Summary

    Itolizumab in Ulcerative Colitis: Executive Summary Strong mechanistic rationale Near term Phase 2 clinical data in GI disease read out • CD6high Teff cells have greater • Itolizumab vs. placebo vs. adalimumab pathogenic potential and are study complete (n=90) associated with GI inflammation • Topli

  16. Slide 16: UC Phase 2 Study – Conducted by Biocon in India

    UC Phase 2 Study – Conducted by Biocon in India Itolizumab Q2W + SoC (Fixed Dose + SoC140 mg) ltolizumab Q2W + SoC N=3 n=30 Primary endpoint: Proportion of subjects who Biologics naive achieved clinical remission Randomization patients with Double Blind Placebo + SoC per Total Mayo Score at moderate

  17. Slide 17: Corporate

    Leadership Corporate Intellectual Property Financials Milestones

  18. Slide 18: Accomplished Executive Leadership

    Accomplished Executive Leadership Bruce Steel, CFA Steve Connelly, PHD Christine Zedelmayer CHIEF EXECUTIVE OFFICER CHIEF SCIENTIFIC OFFICER CHIEF OPERATING OFFICER BioMed Ventures • Rincon BioMed Ventures • aTyr Pharma Amylin • Amgen • Ligand Anaphore • Ambit The Scripps Research Institute Jason Ke

  19. Slide 19: Equillium Intellectual Property & Regulatory Exclusivity

    Equillium Intellectual Property & Regulatory Exclusivity c-Cytokine Family/EQ101 Compositions and Methods c, IL-6, IL-17 Cytokine Families Compositions/Methods Multi-Cytokine Technologies EQ102 Compositions/Methods 6 patent families 98 issued patents 43 applications pending Orally-Delivered Peptid

  20. Slide 20: Equillium Financial Overview & Milestones

    Equillium Financial Overview & Milestones Key Financial Metrics Total Cash and Investments (as of September 30, 2024) $25.9 M Equillium funded into Q4 2025 * Q3 YTD 2024 Operating Burn $15.7 M Itolizumab: aGVHD Shares Outstanding (as of November 8, 2024) 35.4 M Phase 3 EQUATOR study Potential accele

  21. Slide 21: Thank you

    Thank you www.equilliumbio.com

  22. Slide 22: Appendix: Multi-Cytokine Platform & Therapeutic Candidates

    Appendix: Cytokine Challenge Multi-Cytokine Platform Platform & Therapeutic MCi Advantage Candidates EQ101 / EQ302

  23. Slide 23: Cytokines are Validated Drug Targets

    Cytokines are Validated Drug Targets • Cytokines are small signaling proteins with essential roles in immune responses, but when not properly regulated they are key disease drivers Cytokines can exhibit overlapping or synergistic biological activities Cytokine Cytokine Most drugs used to treat autoi

  24. Slide 24: Challenges in Targeting Cytokine Signaling

    Challenges in Targeting Cytokine Signaling mAb JAK inhibitor Ideal Therapeutic Approach Inhibits Only One Cytokine Inhibits 50+ Cytokines Selective inhibition of disease driving cytokines Inhibiting the right Upstream signaling combination of cytokines is key for optimal therapeutic effect, balancin

  25. Slide 25: Multi-Cytokine Inhibitor Platform

    Multi-Cytokine Inhibitor Platform Modular platform generates products that modulate the natural biological redundancy or synergy of cytokines affording greater therapeutic benefit Validated Disease Targets • Technology originating from • Products can be flexibly the National Institutes of Health mod

  26. Slide 26: γC Receptor: A Key Shared Cytokine Signaling Hub

    γC Receptor: A Key Shared Cytokine Signaling Hub Cytokines of the γC receptor are critical regulators of immune responses thus, making it an attractive drug target for modulating T, NK and B cells Overlapping and synergistic signaling on CD4, CD8 & NK cytotoxic T cells β γ α γ α γ α γ β γ α γ Privat

  27. Slide 27: Generation of Selective Multi-Cytokine Inhibitors (MCi)

    Generation of Selective Multi-Cytokine Inhibitors (MCi) •CYTOKINE-RECEPTOR COMPLEX •CYTOKINE D-HELICES •FUNCTIONAL MODIFICATIONS Cytokine Shared IL-2 PK extension strategies receptor IL-4 Private IL-7 PEGylation receptor Lipidation IL-9 IL-15 FC-fused peptibodies IL-21 Analyze native sequences Prote

  28. Slide 28: MCi MoA: Disrupting Assembly of the Receptor Complex

    MCi MoA: Disrupting Assembly of the Receptor Complex Selective inhibition of cytokines A, D & F Cytokines E A F D C B A Multi-cytokine Inhibitor (MCi) % Inhibition A No Signaling Private Shared Receptors Receptor A B C D E F Cytokines E Control +MCi Cytokines first bind to private receptor Multi-cyt

  29. Slide 29: The Multi-Cytokine Inhibitor Advantage

    The Multi-Cytokine Inhibitor Advantage Addressing limitations of single-target biologics and broadly immunosuppressive kinase inhibitors by selectively inhibiting only those cytokines driving disease mAb JAK inhibitor MCi Improved Therapeutic Profile Inhibits One Cytokine Inhibits 50+ Cytokine Inhib

  30. Slide 30: EQ101 & Derm Franchise

    Dashboard & Derm Franchise EQ101 First-in-Class Tri-specific Alopecia Areata (AA) Study inhibitor of IL-2/IL-9/IL-15 Phase 2 AA Data

  31. Slide 31: EQ101: First-in-Class Tri-Specific Cytokine Inhibitor

    EQ101: First-in-Class Tri-Specific Cytokine Inhibitor Inhibition of the key cytokines IL-2, IL-9 and IL-15 by EQ101 has shown an ability to translate from preclinical models into humans IL-2 IL-9 IL-15 • IL-2 & IL-15 are important • PEGylated peptide • As active as ruxolitinib in • Significant clini

  32. Slide 32: EQ101: Valuable Medical Dermatology Franchise

    EQ101: Valuable Medical Dermatology Franchise Multi-Billion dollar market opportunity for EQ101 in medical dermatology Large need exists for safe and effective therapies 250,000 US 6.6M US 24,000 adult 1.5M+ US moderate-severe moderate- US Patients1 Patients3 Patients2 severe Patients4 Cutaneous T c

  33. Slide 33: EQ101: More Complete Downstream Signal Inhibition Versus JAKi

    EQ101: More Complete Downstream Signal Inhibition Versus JAKi JAKi suppression of cytokine signaling is incomplete, while EQ101 inhibits the multiple downstream pathways for complete suppression of cytokine signaling Ruxolitinib blocks EQ101 blocks all JAK/STAT pathway only major pathways α +IL-2 -

  34. Slide 34: EQ101: Clinically Validated in Severe Dermatological Disease

    EQ101: Clinically Validated in Severe Dermatological Disease Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients Phase 1/2 MAD study in Cutaneous Response Rate in Stage IB/II Patients T Cell Lymphoma (n=30) MAVO

  35. Slide 35: EQ101: Positive Proof-of-Concept Opens Up Indication Expansion

    EQ101: Positive Proof-of-Concept Opens Up Indication Expansion ✓ >100 subjects dosed, ✓ Compelling clinical activity ✓ Attractive target product demonstrated favorable observed in cutaneous T cell profile for the treatment of safety and tolerability lymphoma (CTCL) patients CTCL patients ✓ IND open

  36. Slide 36: Large Unmet Need in Alopecia Areata

    Large Unmet Need in Alopecia Areata EQ101 is positioned as a well-tolerated and effective alternative to JAK inhibitors Currently approved and late-stage “I am concerned Blackbox warning ** pipeline drugs are all JAK inhibitors about the safety of There remains a chronic need, oral JAK inhibitors *

  37. Slide 37: EQ101: Targeted Treatment Approach for Alopecia Areata

    EQ101: Targeted Treatment Approach for Alopecia Areata IL-2, IL-9 and IL-15 are key drivers of disease in alopecia areata, promoting a cycle of increased IFN-γ production and immune cell attack of the hair follicle Hair follicle bulb IFN-γ CD4 IL-2 Drives inflammation IL-15 & hair loss IL-9 NK CD8 I

  38. Slide 38: EQ101 Reverses Immune-Mediated Hair Loss in a Mouse Model

    EQ101 Reverses Immune-Mediated Hair Loss in a Mouse Model EQ101 is more effective than ruxolitinib at hair regrowth and suppression of cytotoxic CD8+ T cells in humanized alopecia model EQ101 Improves Hair Regrowth EQ101 Reduces CD8+ Cytotoxic T-cell Activation Marker NKG2D 140 EQ101 2 mg/kg 120 IV

  39. Slide 39: SALT Response Varies by Baseline Severity & Dose

    SALT Response Varies by Baseline Severity & Dose Patients with very severe disease have been shown to be slower to respond and need increased dosing and longer treatment Baricitinib 2-mg Baricitinib 4-mg SALT Score ≤20 Response Rate SALT Score ≤20 Response Rate * * Severea: baseline SALT score of 50

  40. Slide 40: Comparative Data: SALT ≤20 at Week 24

    Comparative Data: SALT ≤ 20 at 24 Weeks Consistently low placebo rates observed: average of 3.6% Dose-dependent drug activity observed: range of 11% - 33% in Phase 2 & 3 studies % Patients achieving SALT ≤ 20 50 SALT ≤ 20 at week 24 High dose JAKi 40 Low dose JAKi Therapeutic Signal Placebo 30 20 10

  41. Slide 41: Comparative Data: SALT Change from Baseline at Week 24

    Comparative Data: SALT Change from Baseline at 24 Weeks Consistently low placebo rates observed: average of 3.2% Dose-dependent drug activity observed: range of 17% - 45% in Phase 3 studies 50 SALT % change from baseline at week 24 % Change from Baseline 40 Therapeutic Signal High dose JAKi 30 Low d

  42. Slide 42: Phase 2 Study of EQ101 in Adults With Moderate to Very Severe AA

    Phase 2 Study of EQ101 in Adults With Moderate to Very Severe AA Phase 2 Open Label Study Design Potential Target Product Profile Screening Treatment Follow-Up 5 weeks 24 weeks 4 weeks Safer alternative to JAKi 2 mg/kg QW IV bolus push with comparable efficacy Patient-administered weekly/bi- Populat

  43. Slide 43: Safety Summary: TEAEs

    Safety Summary: TEAEs EQ101 exhibited a favorable safety and tolerability profile with no SAEs, similar to the safety profile observed in prior Phase 1 & 2 studies (SAD/MAD NHVs, LGLL and CTCL populations) SAFETY OVERVIEW Most TEAEs were Only 2 CTCAE Grade 3 TEAEs • >70% of subjects had a medical CT

  44. Slide 44: Key SALT Response Data by Subgroup: Completed Subjects

    Key SALT Response Data by Subgroup: Completed Subjects SALT responses exceed historical placebo rates: greater improvements in moderate and severe subjects (SALT 35 to <95) compared with those with very severe disease (SALT 95+) SALT ≤ 20 Mean SALT SALT Mean SALT @ n (%) @ W24 Improvement from Basel

  45. Slide 45: EQ302 & Celiac Disease (CeD)

    Dashboard & Celiac Disease (CeD) EQ302 First-in-Class, Orally Delivered CeD Opportunity Bi-specific inhibitor of IL-15 & IL-21

  46. Slide 46: EQ302: First-in-class Bi-Specific Cytokine Inhibitor

    EQ302: First-in-class Bi-Specific Cytokine Inhibitor IL-15 & IL-21 are key cytokines driving GI inflammation in celiac disease and IBD IL-15 IL-21 • IL-15 and IL-21 important • Based on the D-helix • Inhibits the IL-15 & IL-21 • EQ302 Lead candidate to T and B cell biology of γc cytokines selectivel

  47. Slide 47: EQ302: Valuable Gastrointestinal Franchise

    EQ302: Valuable Gastrointestinal Franchise Multi-Billion dollar market opportunity for EQ302 as an orally delivered bi-specific cytokine inhibitor for multiple GI indications >750,000 US 2,700,000 adult >350,000 US GFD non-responders2 US Patients1 Patients3 IBD: Crohn's & Colitis Celiac Disease Eosi

  48. Slide 48: No Approved Therapies For Celiac Disease

    No Approved Therapies For Celiac Disease Celiac Disease: • Autoimmune disease triggered by consuming gluten resulting in damage to GI tract • Symptoms include vomiting, diarrhea, abdominal pain, anemia and fatigue • Many patients non-responsive to strict gluten free diet, experiencing ongoing GI inf

  49. Slide 49: Celiac Disease: Destructive Immune-mediated GI Disease

    Celiac Disease: Destructive Immune-mediated GI Disease IL-15 & IL-21 synergistically drive inflammatory T & B cell responses resulting in tissue damage in celiac patients Autoantibodies Gluten IL-21 Gluten-specific CD4+ cells Healthy Epithelial cell death Gut Epithelium and villous atrophy IL-15/IL-

  50. Slide 50: A Targeted Treatment Approach for Celiac Disease

    A Targeted Treatment Approach for Celiac Disease Dual inhibition of pathogenic IL-15 & IL-21 pathways that cause inflammation and tissue damage can maintain healthy gut epithelium IL-15/IL-21 Inhibitor Inhibition of Granzyme B expression in CeD IE-CTLs Gluten IL-21 stimulated with IL-15 & IL-21 5,00

  51. Slide 51: Opportunity in Celiac Disease

    Opportunity in Celiac Disease EQ302 selectively targets the underlying immune pathophysiology, and the targeted approach aligns with FDA guidance to treat inflammation Approaches to Treating Celiac Disease Increasing Regulatory Clarity and Strategic Interest in Celiac Disease reduce restore promote

Equillium — Investor Presentation (November 2024) on 6ix